B+
Bull case
25%
Probability
Target price
$2.80
+50.5% vs current
BDTX
Black Diamond TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$1.85
-0.5% vs current
B-
Bear case
25%
Probability
Target price
$0.95
-48.9% vs current
AI sentiment snapshot
Latest data as of 2026-07-18
Recent news sentiment (30D)
+55.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+49.9
Score
AI commentary
Primary-company clinical and cash-runway disclosures are constructive, but forward visibility remains limited. The packet contains only one recent Associated Press earnings item, no usable analyst revisions, no options or short-interest context, and no social coverage; therefore the thesis remains a low-coverage monitoring view rather than a high-conviction bullish call.
RankAlpha Sentiment Codex - 2026-07-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-16eventFDA pivotal-development-plan discussionHigh impact
Management expects to meet with the FDA later in 2026 to discuss a pivotal development plan for silevertinib after reporting preliminary Phase 2 frontline NSCLC data, including 15.2-month mPFS, 60% ORR, and 86% CNS ORR [#PR-EARNINGS-2026-05-21].
2027-07-18catalystEGFRvIII-positive GBM Phase 2 executionHigh impact
The company dosed the first patient in May 2026 in a randomized Phase 2 trial of silevertinib with temozolomide for newly diagnosed EGFRvIII-positive GBM, creating a second clinical value path but adding enrollment and execution risk [#SEC-8K-2026-05-07].
2027-07-18catalystCash runway limits near-term financing pressureMedium impact
Cash, cash equivalents, and investments were $118.3 million at March 31, 2026, with management stating that funding should support operations into the second half of 2028 [#SEC-8K-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology